COR Therapeutics, Inc. Confirms Prior Guidance for Profitable Fourth Quarter of 2001 and for Sales of INTEGRILIN in 2001
COR Updates 2001 INTEGRILIN® Sales Estimates
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Jan. 7, 2002--COR Therapeutics, Inc. (Nasdaq: CORR - news) today confirmed prior guidance of a profit for the fourth quarter and for the full year of 2001, based on unaudited financial data. COR also said that year-end 2001 sales of INTEGRILIN® (eptifibatide) Injection, as reported to COR by its worldwide partner for INTEGRILIN, Schering-Plough Corporation, would be approximately $208 million in the United States and approximately $230 million on a worldwide basis, at the high end of the range of $225 - $230 million worldwide included in guidance previously provided. COR noted that this represents a 34% increase over worldwide sales reported for 2000.
COR Therapeutics, Inc. is dedicated to the discovery, development, and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases.
In addition to the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from the anticipated results discussed in such forward-looking statements, due to factors related to the commercialization of INTEGRILIN and other factors discussed in the Company's SEC reports, including, but not limited to, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2001, and Annual Report on Form 10-K for the year ended December 31, 2000. Forward-looking statements are based on current expectations and the Company does not intend to update such information to reflect later events or developments.
--------------------------------------------------------------------------------
Contact:
COR Therapeutics, Inc.
Peter S. Roddy
Catherine C. Villegas
650/244-6893
or
Burns McClellan, Inc.
Media:
Lisa Burns
Jonathan M. Nugent
212/213-0006 |
